OverviewSuggest Edit

Aetion is a healthcare technology company that delivers the real-world analytics and evidence needed for value-based healthcare. With its patented rapid-cycle analytics technology, the platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in patient care.

TypePrivate
Founded2013
HQNew York, NY, US
Websiteaetion.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Sept 2021)211(+2%)
Cybersecurity ratingBMore

Key People/Management at Aetion

Carolyn Magill

Carolyn Magill

Chief Executive Officer and Director
Jeremy Rassen

Jeremy Rassen

Co-Founder, President, Chief Science Officer, and Board Director
Scott Gottlieb

Scott Gottlieb

Director
Lori Bennett

Lori Bennett

General Counsel
John Turek

John Turek

Chief Technology Officer
Lowell Schiller

Lowell Schiller

Chief Legal and Regulatory Officer
Show more

Aetion Office Locations

Aetion has offices in New York, Boston, El Segundo and Bougival
New York, NY, US (HQ)
5 Pennsylvania Plaza 7th floor
Boston, MA, US
50 Congress St #1025
El Segundo, CA, US
840 Apollo St #100
Bougival, FR
40 Chemin de l'Ariel
Show all (4)

Aetion Financials and Metrics

Summary Metrics

Founding Date

2013

Aetion total Funding

$203.6 m

Aetion latest funding size

$110 m

Time since last funding

4 months ago

Aetion investors

Aetion's latest funding round in May 2021 was reported to be $110 m. In total, Aetion has raised $203.6 m
Show all financial metrics

Aetion Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Aetion Online and Social Media Presence

Embed Graph

Aetion News and Updates

Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization

Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies

Aetion and Cegedim Health Data Announce Long-Term Partnership to Expand Real-World Evidence Research in Europe

 Collaboration will power an RWE solution to assess the utilization, safety, and effectiveness of treatments in near real-time, across Europe

ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema

BOSTON and NEW YORK, April 12, 2021 /PRNewswire/ -- The Institute for Clinical and Economic Review (ICER) today announced it is using observational real-world evidence (RWE) to update its 2018 assessment of three therapies for long-term prophylaxis against hereditary angioedema (HAE)...

Aetion cracks top 10 of Fast Company’s 100 Best Workplaces for Innovators

The healthcare company checks in at number 10. The healthcare technology company uses data and predictive modeling to answer questions about how certain treatments will affect different sectors of the population. The company has a separate labs team completely focused on innovation. The labs team, s…

FDA, Aetion team up to find answers around COVID-19 risk factors, treatments

By using real-world patient information, the agency hopes to research population health trends and medication efficacy.

Drug pricing review group signs deal with Aetion for patient data

The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly.
Show more

Aetion Blogs

ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology

This year at ICPE All Access, Aetion’s scientific research was represented across symposia, presentations, and posters, including some initial findings from our COVID-19 research collaboration with the U.S. Food and Drug Administration (FDA) and our continued efforts to advocate for best practices i…

ICPE Research Spotlight 2021: Part I: Findings from Aetion-FDA research collaboration to advance understanding of COVID-19 with RWE

This year at ICPE All Access, Aetion’s scientific research is represented across symposia, presentations, and posters, including some initial findings from our COVID-19 research with the U.S. Food and Drug Administration (FDA) and our continued efforts to advocate for best practices in pharmacoepide…

RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot

In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review (ICER) stated its intent to pilot the use of real-world evidence (RWE) for reassessments of drugs that received accelerated approval from the U.S. Food and Drug Administration (FDA). ICER’s goal in this pilot is to…

Patient Voice in RWE: Generating evidence that will impact payer and HTA decision-making

With the rise of patient-centered medicine and accelerated approvals, health technology assessment (HTA) bodies and payers are looking to real-world evidence (RWE) to strengthen evidence packages and reduce uncertainties at the time of launch. Increasingly, stakeholders are recognizing the importanc…

RWE Guidance Watch: IMPACT HTA publishes recommendations on the use of RWE in HTA

As researchers await comprehensive guidance on the use of real-world evidence (RWE)—and acknowledge the gaps in existing RWE best practice recommendations—many organizations, including regulators, health technology assessment (HTA) bodies, and other decision-makers, are currently developing guidance…

An update on efforts to standardize and democratize RWE: Q&A with Dr. Nirosha Mahendraratnam Lederer

As real-world evidence (RWE) adoption continues to ramp up across health care, researchers have increasingly recognized the importance of implementing standardized methods for evaluating and analyzing real-world data (RWD). In developing these standards and making them accessible to a wide range of …
Show more

Aetion Frequently Asked Questions

  • When was Aetion founded?

    Aetion was founded in 2013.

  • Who are Aetion key executives?

    Aetion's key executives are Carolyn Magill, Jeremy Rassen and Scott Gottlieb.

  • How many employees does Aetion have?

    Aetion has 211 employees.

  • Who are Aetion competitors?

    Competitors of Aetion include IQVIA, Stellar Health and CyberMDX.

  • Where is Aetion headquarters?

    Aetion headquarters is located at 5 Pennsylvania Plaza 7th floor, New York.

  • Where are Aetion offices?

    Aetion has offices in New York, Boston, El Segundo and Bougival.

  • How many offices does Aetion have?

    Aetion has 4 offices.